Molbio Diagnostics IPO Lists at 21% Premium on Dalal Street
Molbio Diagnostics’ successful market debut at an Indian stock exchange.
Key Highlights
Molbio Diagnostics makes a strong market debut, listing at a 21% premium over its IPO price of ₹807 on the BSE and NSE. Explore the details of this successful IPO.
Molbio Diagnostics recorded a robust market debut on Monday, August 17, with its shares listing at a 21% premium on Dalal Street. The initial public offer () price for the company stood at ₹807 per share.
Shares commenced trading at ₹980 on both the and (NSE), reflecting a 21.44% premium above the issue price. This performance notably exceeded grey market premium () expectations, which had suggested a 15% listing gain with a GMP of ₹120.
Key Listing Metrics
- IPO Price: ₹807
- Listing Price (BSE & NSE): ₹980
- Listing Premium: 21.44%
- GMP Expectation: 15% gain, ₹120 GMP
Shivani Nyati, Head of Wealth at Swastika Investmart, attributed the strong debut to Molbio Diagnostics’ leadership in molecular diagnostics. She also cited the company’s expansion-focused growth strategy and the attractive industry outlook as supporting the investment case.
IPO Details and Overview
The ₹940 crore Molbio Diagnostics IPO consisted of a fresh issue worth ₹200 crore and an offer for sale totaling ₹739.70 crore. The public offer was open for bidding from August 10 to August 12, with a price band between ₹768 and ₹807 per share.
- Bidding Period: August 10 to August 12
- : ₹768–₹807 per share
- : 18 shares
- Total Bids Received: 573.21 million shares
- Shares on Offer: 8.15 million shares
The IPO garnered an overwhelming response, achieving a subscription of 70.26 times overall. The qualified institutional buyer () segment was subscribed 186.39 times, while non-institutional investors () and retail quotas were booked 49.80 times and 12.96 times, respectively.
Outlook and Capital Allocation
Molbio Diagnostics specializes in developing, manufacturing, and commercializing point-of-care (POC) molecular diagnostic platforms. The company focuses on rapid, accurate, and cost-effective solutions for infectious and non-communicable diseases.
- Fresh Proceeds Allocation: Capital expenditure for R&D facilities and a Centre of Excellence
- Additional Investment: Plant and machinery for Goa and Visakhapatnam facilities
- General Use: General corporate purposes
Nyati advised investors to maintain discipline despite the initial sharp gain, recommending a stop-loss of ₹900. Kotak Mahindra Capital, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors served as the book-running lead managers for the IPO.